Acid-labile interferon alpha concentration: Prognostic value during immune reconstitution following effective antiretroviral therapy in HIV-1-positive patients

HIV and AIDS Review

Volumn 5, Issue 3, 2006, Pages 7-12

  Knysz, Brygida ^a   Rybka, Katarzyna ^b   Gasiorowski, Jacek ^a   Plasecki, Egbert ^b,c   Zalewska, Małgorzata ^a   Gładysz, Andrzej ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^c JAN DLUGOSZ UNIVERSITY   (Poland)

Author keywords

Acid labile interferon alpha; cART; HIV 1 infection; Immune reconstitution

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; VIRUS RNA;

ADOLESCENT; ADULT; ARTICLE; BIOASSAY; BLOOD ANALYSIS; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE STATUS; IMMUNOSTIMULATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; VIRUS REPLICATION;

EID: 33846484958     PISSN: 17301270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, Knysz B, Dietrich M, Phillips AN, Lundgren JD; EuroSIDA study group. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362(9377): 22-9.
2. Florence E, Lundgren J, Dreezen C, Fisher M, Kirk O, Blaxhult A, Panos G, Katlama C, Vella S, Phillips A, EuroSIDA Study Group. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med 2003; 4(3): 255-62.
3. Miller V, Mocroft A, Reiss P, Katlama C, Papadopoulos AI, Katzenstein T, van Lunzen J, Antunes F, Phillips AN, Lundgren JD. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med 1999; 130(7): 5 70-7.
4. Chehadeh W, Chabou S, Fontier C, Alm G, Lon G, Boket L, Mouton Y, Wattre P, Hober D. In HIV-1-infected patients, plasma levels of HIV-1 RNA are inversely correlated with IFN-alpha responsiveness of whole-blood cultures to sendai virus. J Clin Virol 2000; 16(2): 123-8.
5. Miller V, Phillips AN, Clotet B, Mocroft A, Ledergerber B, Kirk O, Ormaasen V, Cargalianos-Kakolyris P, Vella S, Lundgren JD. Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis 2002; 186(2): 189-97.
6. Capobianchi MR, Ameglio F, Cordiali Fei P, Castilletti C, Mercuri F, Fais S, Dianzani F. Coordinate induction of interferon alpha and gamma by recombinant HIV-1 glycoprotein 120. AIDS Res Hum Retroviruses 1993; 9(10): 957-62.
7. Capobianchi MR, Mattana P, Mercuri F, Conciatori G, Ameglio F, Ankel H, Dianzani F. Acid lability is not an intrinsic property of interferon-alpha induced by HIV-infected cells. J Interferon Res 1992; 12(6):431-8.
8. Piasecki E. Human acid-tabile interferon alpha. Arch Immunol Ther Exp 1999; 47(2): 89-98.
9. Piasecki E, Knysz B, Gasiorowski J, Gladysz A. Decrease of enhanced interferon alpha levels in sera of HIV-infected and AIDS patients receiving combined antiretroviral therapy. Arch Immunol Ther Exp 1999; 47(1): 37-44.
10. Piasecki E, Knysz B, Inglot M, Simon K, Gladysz A. Long-term assessment of interferon responses in the HIV+ and AIDS patients. Arch Immunol Ther Exp 1996; 44(5-6): 345-52.
11. Piasecki E, Ledwon TK, Inglot AD, Knysz B, Simon K, Inglot M, Gladysz A. Interferon and tumor necrosis factor responses of HIV+ patients as markers for monitoring of the AIDS progression. Arch Immunol Ther Exp 1994; 42(5-6): 439-45.
12. Inglot A.D., Młochowski J., Zielińska-Jenczytik J., Piasecki E., Ledwoń T.K., Kloc K.: Seleno-organic compounds as immunostimulants: an approach to the structure-activity relationship. Arch. Immunol. Ther. Exp 1996; 44: 67-75.
13. Hansen M.B., Nielsen S.E., Berg K.: Re-examination and further development of a precise and rapid dye method for measuring cell growth/ cell kill. J. Immunol. Methods 1989; 119: 203-210.
14. Abbate I, Dianzani F, Capobianchi MR. Activation of signal transduction and apoptosis in healthy lymphomonocytes exposed to bystander HIV-1-infected cells. Clin Exp Immunol 2000; 122(3): 374-80.
15. Vicenzi E, Biswas P, Mengozzi M, Poh G. Role of pro-inflammatory cytokines and beta-chemokines in controlling HIV replication. J Leukoc Biol 1997; 62(1): 34-40.
16. Poli G, Biswas P, Fauci AS. Interferons in the pathogenesis and treatment of human immunodeficiency virus infection. Antiviral Res 1994; 24(2-3): 221-33.
17. Lange CG, Lederman MM. Immune reconstitution with antiretroviral therapies in chronic HIV-1 infection. J Antimicrob Chemother 2003; 51(1): 1-4.
18. Carcelain G, Debre P, Autran B. Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following andretroviral therapy. Curr Opin Immunol 2001; 13(4): 483-8.
19. Plana M, Martinez C, Garcia F, Malerio MJ, Barcelo JJ, Garcia A, Lejeune M, Vidal C, Cruceta A, Miro, JM, Pumarola T, Gallart T, Gatell JM. Immunologic reconstitutiori after 1 year of highly active antiretroviral therapy, with or without protease inhibitors. J Acquir Immune Defic Syndr 2002; 29(5): 429-34.
20. Valdez H, Connick E, Smith KY, Lederman MM, Bosch RJ, Kim RS, St Clair M, Kuritzkes DR, Kessler H, Fox L, Blanchard-Vargas M, Landay A, AIDS Clinical Trials Group Protocol 375 Team. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002; 16(14): 1859-66.
21. Viard JP, Burgard M, Hubert JB, Aaron L, Rabian C, Pertuiset N, Lourenco M, Rothschild C, Rouzioux C. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 2004; 18(1): 45-9.